Brandname drug bioequivalence
Executive Summary
House Government Operations/Intergovernmental Relations Subcommittee Chairman Weiss (D-N.Y.) asked FDA for inspection reports that were conducted in the last two years and contain bioequivalence analyses. In the Sept. 25 request, Weiss specified that he wanted reports on "non-generic, brandname pharmaceuticals." FDA has not yet responded.